Poseida Therapeutics Overview
- Founded
-
2014
- Status
-
Public
- Employees
-
314
- Stock Symbol
-
PSTX
- Investments
-
1
- Share Price
-
$3.18
- (As of Tuesday Closing)
Poseida Therapeutics General Information
Description
Poseida Therapeutics Inc is a clinical-stage biopharmaceutical company focused on leveraging non-viral gene engineering technologies to create life-saving therapeutics for patients with a high unmet medical need. It has built a pipeline of autologous and allogeneic chimeric antigen receptor T cell, or CAR-T, product candidates, initially focused on the treatment of hematological malignancies and solid tumours.
Contact Information
Primary Industry
Drug Discovery
Other Industries
Pharmaceuticals
Biotechnology
Stock Exchange
NAS
Primary Office
- 9390 Towne Center Drive
- Suite 200
- San Diego, CA 92121
- United States
+1 (858) 000-0000
Poseida Therapeutics Timeline
Poseida Therapeutics Stock Performance
(As of Tuesday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $3.18 | $3.37 | $1.82 - $8.82 | $292M | 85.9M | 633K | -$0.44 |
Poseida Therapeutics Financials Summary
|
In Thousands, USD |
TTM 30-Sep-2022 | FY 2022 31-Dec-2022 | FY 2021 31-Dec-2021 | FY 2020 31-Dec-2020 |
|---|---|---|---|---|
| EV | 251,785 | 267,180 | 287,985 | 395,582 |
| Revenue | 151,679 | 31,238 | 0 | |
| EBITDA | (18,728) | (117,064) | (123,683) | |
| Net Income | (29,215) | (124,974) | (129,775) | |
| Total Assets | 380,481 | 269,309 | 371,484 | |
| Total Debt | 90,633 | 61,198 | 59,315 |
Public Fundamental Data provided by Morningstar, Inc.
disclaimer
Poseida Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Poseida Therapeutics Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price |
% Owned |
|---|
Poseida Therapeutics Comparisons
Description
Primary
Industry
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Financing
Details
Poseida Therapeutics Inc is a clinical-stage biopharmaceutical company focused on leveraging non-viral gene engineering
Drug Discovery
San Diego, CA
314
As of 2022
00000
0000
0000-00-00
00000000
00000
000 00
t. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore
0000 000000000
Cambridge, MA
000
As of 0000
00000
00000000
00000
000000
olore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident,
0000000000000
New York, NY
000
As of 0000
00000
0000000000
00000
Add Comparison
Poseida Therapeutics Competitors (49)
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Vor Biopharma | Formerly VC-backed | Cambridge, MA | 000 | 00000 | 00000000 | 00000 |
| 0000000 000 | Corporation | New York, NY | 000 | 00000 | 0000000000 | 00000 |
| 00000000 000000000 | Formerly VC-backed | Newtown, PA | 00 | 00000 | 00000000 | 00000 |
| 00000000 000000000 | Formerly VC-backed | San Diego, CA | 000 | 00000 | 0000000000. | |
| 00000000 | Formerly VC-backed | Tubingen, Germany | 000 | 00000 | 000000000 | 00000 |
Poseida Therapeutics Patents
Poseida Therapeutics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| AU-2021255869-A1 | Compositions and methods for use in the treatment of cancer | Pending | 14-Apr-2020 | 0000000000000 | |
| CA-3174777-A1 | Compositions and methods for use in the treatment of cancer | Pending | 14-Apr-2020 | 0000000000000 | |
| EP-4135758-A1 | Compositions and methods for use in the treatment of cancer | Pending | 14-Apr-2020 | 0000000000000 | |
| EP-4118107-A1 | Chimeric stimulatory receptors and methods of use in t cell activation and differentiation | Pending | 11-Mar-2020 | 00000000000 | |
| AU-2021230361-A1 | Compositions and methods for the treatment of metabolic liver disorders | Pending | 04-Mar-2020 | C12N15/86 |
Poseida Therapeutics Executive Team (14)
Poseida Therapeutics Board Members (14)
| Name | Representing | Role | Since |
|---|---|---|---|
| Charles Baum Ph.D | Self | Board Member | 000 0000 |
| Cynthia Collins | Self | Board Member | 000 0000 |
| David Hirsch Ph.D | Longitude Capital | Board Member | 000 0000 |
| John Schmid | Self | Board Member | 000 0000 |
| Mark Gergen JD | Poseida Therapeutics | Chief Executive Officer & Board Member | 000 0000 |
Poseida Therapeutics Signals
Growth Rate
0.80%
Weekly
Growth
Growth
Weekly Growth
0.80%, 93rd %
-35.5%.
530%
Size Multiple
219x
Median
Size Multiple
219x, 100th %ile
0.00x
0.95x.
413Kx
Key Data Points
Twitter Followers
5.5k
Similarweb Unique Visitors
15.0K
Majestic Referring Domains
314
Poseida Therapeutics Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
Poseida Therapeutics Acquisitions (1)
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| 0000000 00000 | 10-Oct-2016 | 0000000000 | 0000 | Drug Discovery |
Poseida Therapeutics ESG
Risk Overview
Risk Rating
Updated July, 12, 2022
27.33 | Med Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
00.0
Management
Management is related to actions taken to manage ESG issues
00.00
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
00 of 14,912
Rank
00.00
Percentile
Pharmaceuticals
Industry
00 of 965
Rank
00.00
Percentile
Biotechnology
Subindustry
00 of 443
Rank
00.00
Percentile
